EUVIMEDEUVIMED entdecken
Crossref

Trends in renal function following vascular endothelial growth factor inhibitor administration in patients with cancer and diabetes mellitus

Yuma Shibutani, Miki Hayakawa, Mayu Ishizaka

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04793-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Yuma Shibutani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Chiba, Japan. yshibuta@east.ncc.go.jp. Hauptthemen laut MEDLINE: Neoplasms, Proteinuria, Vascular Endothelial Growth Factor A, Diabetes Mellitus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vascular endothelial growth factor (VEGF) inhibitors are associated with a high incidence of proteinuria. In patients with diabetes, increased proteinuria is closely associated with decreased renal function; however, the impact of increased proteinuria on renal function in patients with cancer and diabetes mellitus undergoing VEGF inhibitor therapy remains unknown. METHODS: The incidence of proteinuria and renal function in patients with cancer and a history of diabetes who were treated with VEGF inhibitors at the National Cancer Center Hospital East between January 2018 and December 2019 was retrospectively investigated. RESULTS: Among the 49 patients included, 21 (43%) developed proteinuria ≥ 3 + after VEGF inhibitor treatment. In all patients, a decreasing trend in the estimated glomerular filtration rate (eGFR) was observed beginning 2 years after treatment initiation. The decrease in eGFR from baseline was - 6.6% at 1 year, -11% at 2 years, and - 13% at 4 years. Patients who developed proteinuria ≤ 2 + showed no significant decrease in eGFR from baseline to either the end of treatment (p = 0.91) or the latest value during the observation period (p = 0.64). Similarly, no significant decrease in eGFR was observed in those with proteinuria ≥ 3+ (end of treatment, p = 0.91; latest value during the observation period, p = 0.18). CONCLUSIONS: In patients with cancer and diabetes mellitus, increased proteinuria after VEGF inhibitor therapy suggested that it was not associated with a significant decline in renal function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProteinuriaVascular Endothelial Growth Factor ADiabetes MellitusAngiogenesis InhibitorsKidneyHumansMaleFemaleRetrospective StudiesGlomerular Filtration RateMiddle AgedAgedIncidence

Stichwörter der Autor:innen

Diabetes mellitusOnco-nephrologyProteinuriaVascular endothelial growth factor inhibitors

Substanzen

Vascular Endothelial Growth Factor AAngiogenesis InhibitorsVEGFA protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Chiba, Japan. yshibuta@east.ncc.go.jp.
  • Department of Pharmacy, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Chiba, Japan.

Zitieren

APA

Shibutani, Y., Hayakawa, M., & Ishizaka, M. (2025). Trends in renal function following vascular endothelial growth factor inhibitor administration in patients with cancer and diabetes mellitus. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04793-6

Vancouver

Shibutani Y, Hayakawa M, Ishizaka M. Trends in renal function following vascular endothelial growth factor inhibitor administration in patients with cancer and diabetes mellitus. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04793-6

BibTeX
@article{Shibutani2025,
  author = {Shibutani, Yuma and Hayakawa, Miki and Ishizaka, Mayu},
  title = {Trends in renal function following vascular endothelial growth factor inhibitor administration in patients with cancer and diabetes mellitus},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04793-6}
}
Kostenlos starten →